Independent Consulting Agreement (May 5th, 2016)
THIS INDEPENDENT CONSULTING AGREEMENT (the "Agreement"), dated as of March 31, 2016 (the "Effective Date"), is made between OvaScience, Inc., a Delaware corporation, and its successors, subsidiaries and affiliates (collectively, the "Company"), and Dr. Arthur Tzianabos, Ph.D. ("Consultant").
BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS(r) Platform -- Management to Host Conference Call Today at 8:30 a.m. ET to Provide Business Update and Review Fourth Quarter and Fiscal Year 2015 Financial Results -- (March 15th, 2016)
CAMBRIDGE, Mass., March 15, 2016 -- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(r), today reported financial results for the fourth quarter and full year 2015. Additionally, the Company announced a shift in its research and discovery strategy to focus on the development of innovative medicines, primarily in cancer. Moving forward, BIND plans to focus on the development of therapeutics that leverage the ability of ACCURINS(r) to incorporate novel combinations of targeting ligands and unique payloads including oligonucleotides and potent kinase inhibitors, creating synergistic properties in a single particle.
July 15, 2013 Arthur O. Tzianabos, Ph.D. Delivered via Email Dear Arthur, (November 13th, 2013)
On behalf of OvaScience, Inc. (the Company), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer.